INTRODUCTION AND OBJECTIVES: PD-1 blockade have been reported as a promising therapeutic strategy against several solid tumors. However, the unresponsiveness and adverse side effects diminish the therapeutic effects of PD-1 blockade immunotherapy. Nitroxoline, an FDA-approved treatment for urinary tract infections, exhibits anticancer activities by the activation of cell apoptosis, cell cycle arrest, and suppression of angiogenesis. The purpose of this study was to explore whether combining nitroxoline with PD-1 blockade can further improve existing immunotherapy in the mouse prostate cancer orthotopic tumor model. METHODS: We performed XTT and colony formation assays to evaluate the effects of nitroxoline on RM9-LUC-PIRES-KLK3 cell, a mouse prostate cancer cell line, viability and proliferation. The cell cycle distribution were analysed by flow cytometry. And then we investigated the effects of nitroxoline on the PI3K/AKT pathway using western blot analysis. In vivo, stable luciferase-transfected RM9-Luc-pIRES-KLK cells in C57BL/6 mice by orthotopic implantion were imaged with the IVIS imaging system over time. Serum PSA levels in mouse peripheral blood were measured with human PSA ELISA kit. In addition, the expression of CD31 and Ki-67 was evaluated by immune-histochemistry staining. Finally, the percentages of CD44þCD62LþCD8þ memory and TNFaþCD3þCD8þ T cells and myeloid-derived suppressor cells (MDSCs) in peripheral blood cells were quantified by FACS analysis.
RESULTS: We found that nitroxoline markedly inhibited RM9-LUC-PIRES-KLK3 cell proliferation and colony formation in vitro. Nitroxoline also significantly caused cell cycle arrest at S phase. Additionally, we found that nitroxoline treatment reduced protein levels of phospho-AktSer473 and phospho-AktSer308 in a dose-dependent manner. Moreover, their expression further decreased in RM9-LUC-PIRES-KLK3 cells treated with a PI3K inhibitor LY294002, suggesting that the effect of nitroxoline may be mediated by modulation the PI3K/ Akt pathway. Furthermore, examination in the murine RM9-LUC-PIRES-KLK3 prostate cancer orthotopic tumor model revealed that combining nitroxoline with an PD-1 blockade enhanced the anti-tumor efficacy compared to those of nitroxoline or PD-1 blockade monotherapy. These effects included the reduction of tumor weights, luciferinstained images, and serum tumor marker PSA levels, which was accompanied by the infiltration of TNFaþCD3þCD8þ T cells and memory T cells and reduced accumulation of MDSCs.
CONCLUSIONS 
MP65-01 4N1K-PEPTIDE DERIVED FROM THROMBOSPONIDN-2 IS ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND PROGNOSIS IN BLADDER CANCER
Yasuyoshi Miyata, Tsutomu Yuno*, Kyohei Araki, Yuichiro Nakamura, Takuji Yasuda, Yuji Sagara, Tomohiro Matsuo, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Thrombospondins (TSPs) play various important roles under pathological conditions. TSP-1 is well-known and recognised as strong angiogenesis inhibitors in various types of cancers. The 4N1K-peptide (KRFYVVMWKK) is reported to be derived from TSP-1 and TSP-2, and its expression was significantly associated with tumor progression and survival in several cancers. In contrast to TSP-1, pathological significance of TSP-2 and 4N1K-peptide in bladder cancer (BC) are not clear. The main aim is to clarify the pathological roles of TSP-2 and 4N1K-peptide in BC because fewer studies have evaluated them in these patients.
METHODS: We immunohistochemically examined 206 BC tissues for TSP-2, and 4N1K-peptide expressions. Their independent contributions to cancer cell proliferation were measured by anti-Ki-67 antibody; apoptosis was measured by anti-cleaved caspase-3 antibody; angiogenesis was measured by anti-CD34 antibody, and MMP-9 immunoreactivity was also examined in these tissues.
RESULTS: TSP-2 expression was negatively associated with T stage (P < 0.001), metastasis (P ¼ 0.021), and grade (P ¼ 0.018). Similar negative relationships were also detected with respect to 4N1K-peptide expression (P < 0.001, 0.025, and 0.002, respectively). TSP-2 expression was negatively associated with cell proliferation (P ¼ 0.005) and MMP-9 expression (P < 0.001), whereas 4N1K-peptide was significantly associated with apoptosis (P < 0.001), angiogenesis (P ¼ 0.024), and MMP-9 expression (P ¼ 0.005). Subsequently, when the independent role of TSP-2 or 4N1K-peptide was investigated by using a multivariate analysis model, including all pathological features, TSP-2 expression was significantly associated with MMP-9 expression (odds ratio ¼ 0.33, 95% confidential interval, CI ¼ 0.17e0.64, P ¼ 0.001). A similar independent correlation was detected between 4N1K-peptide expression and MVD (odds ratio ¼ 0.52, 95% CI ¼ 0.29e0.95, P ¼ 0.033). In survival analyses, multivariate analyses e858 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 showed that 4N1K-peptide expression was a significant predictor for subsequent metastasis (hazard ratio, HR ¼ 3.90, 95% CI ¼ 1.68e9.07, P ¼ 0.002) and overall survival (HR ¼ 2.43, 95% CI ¼ 1.12e4.86, P ¼ 0.012). CONCLUSIONS: Our results demonstrated that TSP-2 and 4N1K-peptide played important roles in the malignant aggressiveness and progression of BC via complex mechanisms involving cell proliferation, apoptosis, angiogenesis, and MMP-9 expression. We suggested that TSP-2 and 4N1K-peptide are potential therapeutic targets and useful predictor for prognosis in patients with BC.
Source of Funding: None.
MP65-02 DIAGNOSTIC CLASSIFICATION OF CYSTOSCOPIC IMAGES USING DEEP CONVOLUTIONAL NEURAL NETWORK
Okyaz Eminaga*, Cologne, Germany; Axel Semjonow, Muenster, Germany; Bernhard Breil, Krefeld, Germany INTRODUCTION AND OBJECTIVES: The current study aims to evaluate the application of deep learning for the diagnostic classification of cystoscopic images obtained from the cystoscopic examination, which is indicated during the urologic evaluations.
METHODS: Four-hundred-seventy-nine cases representing 44 urologic findings were considered for our pilot study. The image color was linearly normalized and equalized by applying the contrast Limited adaptive histogram equalization. Because these findings can be viewed from every possible angles and side by cystoscopy, we ultimately generated images rotated by 10 grades and flipped vertically or horizontally, thereby resulting in 18,681 images. After image preprocessing, we developed different deep convolutional neural network (CNN) models (i.e., "ResNet50", "VGG-19", "VGG-16", "InceptionV3", and "Xception") and evaluated these models by F1-score. Further, we proposed two CNN concepts (i.e., 90%-filter size of the previous layer and harmonic-series filter size). A training set (60%), a validation set (10%) and a test set (30%) were randomly generated from the study dataset. All models were trained on the training set, validated on the validation set and evaluated on the test set.
RESULTS: The XCeption-based model achieved the highest F1-score of 99.52% and followed by models based on ResNet50 and the harmonic-series concept, which showed F1-scores of 99.48% and 99.45%, respectively. These models could identify all cystoscopic images with bladder cancer correctly. When we focus on the images misclassified by the model with the best performance, 7.86% of images showing bladder stones with indwelling catheter, and 1.43% of Bladder diverticulum were falsely classified.
CONCLUSIONS: The results of the current study underline the potential of deep learning in diagnostic classification for cystoscopic images. Our future work will focus on integrating AI-aided cystoscopy into clinical routine.
Source of Funding: None

MP65-03 GENOMIC ANALYSIS ON SUBJECTS EXPOSED TO ARSENIC IDENTIFIES GENETIC RISK VARIANTS ASSOCIATED WITH BLADDER CANCER AND VARIANTS UNDER RECENT ADAPTIVE SELECTION
Mario Fernandez*, Lucas Vicuña, Santiago, Chile; Patricio Valdebenito, Eduardo Chaparro, Antofagasta, Chile; Cecilia Vial, Annemarie Ziegler, Alberto Bustamante, Susana Eyheramendy, Santiago, Chile INTRODUCTION AND OBJECTIVES: Only a small fraction of arsenic-exposed subjects is affected by malignant diseases. This suggests the existence of genetic risk factors influencing susceptibility to arseniasis and its consequences, such as bladder cancer (BC). Here, we evaluate this hypothesis by performing a case-control genome-wide association study (GWAS) for BC in subjects exposed to significantly elevated drinking-water arsenic levels in Northern Chile. Furthermore, since native people of this region have been exposed for thousands of years to arsenic present in underground water due to volcanic activity, they and their descendants might have adapted to this selective pressure. Therefore, we tested for adaptive selection since we also hypothesized that control subjects from this cohort might have inherited protective genetic variants METHODS: Demographic and clinical data were collected using a structured questionnaire and a blood sample was obtained. DNA samples were analyzed using Affymetrix Genome-Wide SNP Array 6.0. After filtering by missingness per individual and per marker allele frequency and Hardy Weinberg Equilibrium we obtained 788,705 SNPs to be analyzed. Estimates of adaptive (Darwinian) selection by comparing allele frequencies that are unusually high in one vs. two related populations was performed using the Population Branch Statistics (PBS) test.
RESULTS: Several associations reaching genome-wide significance were identified after adjusting for global ancestry, age, sex, smoking habit and occupational risk factors. Whereas some of these variants mapped in genes without a previous relation to BC and thus constitute novel candidates for BC carcinogenesis, others were located in genes related to BC. For instance, an intron variant associated with CTNNA2, a gene linked to BC after undergoing epigenetic modifications in response to arsenic exposure. We further found a variant close to CHL1, which has been associated with arsenic toxicity in cell lines and also to occurrence of BC by acting as a tumor suppressor. PBS test found several candidate variants for adaptive selection in the control group when compared to populations from Asia (CHB/JPT) and Central/ North America (Maya/Nahua). Several of these variants have also been associated with BC and arsenic-related processes, including two intron variants in CTNNA2 CONCLUSIONS: The results of this study contribute to a better understanding of the genetic factors affecting BC in subjects exposed to arsenic and shed light into the recent evolutionary history of Native Americans. Candidate risk SNPs identified need to be further validated in independent analyses Source of Funding: Fondecyt Regular 1120987, Conicyt, Chile
MP65-04 LONG NON-CODING RNA GAS5 MODULATES GEMCITABINE EFFICACY IN BLADDER CANCER VIA REGULATION OF DEOXYCYTIDINE KINASE EXPRESSION
Wei Chen*, Junlong Zhuang, Wenmin Cao, Wenli Diao, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Gemcitabine is a common used agent for therapy in bladder cancer. Our objective was to characterize the ability of Long non-coding RNA GAS5 to modulate the gemcitabine efficacy.
METHODS: Expression of GAS5 was analyzed using real-time quantitative polymerase chain reaction (RT-qPCR) in 30 patients following radical cystectomy and gemcitabine treatment. All subjects signed written informed consent. The study was approved by the Hospital Ethics Boards prior to initiation. The correlation between GAS5 and deoxycytidine kinase (DCK) was further examined by evaluating DCK expression in cells that either overexpressed or knocked down GAS5. Gemcitabine efficacy was identified by CCK-8 assays. DCK and HuR were analyzed by western blotting and immunofluorescence.
RESULTS: GAS5 was significantly downregulated in bladder cancer tissues compared with the paired adjacent non-tumorous tissues. Lower GAS5 expression levels were associated with advanced pathological stages and poor overall survival (Fig. 1) . LncRNA GAS5 expression is also lower in T24, 5637 and SW780 compared with the human normal urothelial cell line (Sv-Huc-1). GAS5 level was well correlated with the sensitivity of the cancer cells toward gemcitabine. Gemcitabine can dose-dependently increase GAS5 level in bladder cancer cells. Of note, pretreated gemcitabine attenuated GAS5-induced with a second dose of gemcitabine. GAS5-overexpressing cells
